Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


'Bio-better' headed for Aust

Posted 4 March 2021 PM

The behind-the-scenes fight for Humira's $312 million market just got hotter with Celltrion Healthcare confirming plans to register pain-free version Yuflyma "at the earliest opportunity".

Humira is yet to see a single competitor on the PBS but a number are waiting in the wings including Amgen's Amgevita, Fresenius Kabi's Idacio, Samsung Bioepis' Hadlima and Sandoz's Hyrimoz. Except Amgevita, all are the older formulation, which contains citrate, an acid known to cause a burning and painful effect upon injection.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas